Yum Brands, the parent company of Pizza Hut and KFC, recently reported a mixed quarter as both of these brands experienced declining same-store sales. The CEO, David Gibbs, attributed these challenges to the impacts of the Middle East conflict and a more cost-conscious consumer base. This has created headwinds for same-store sales at both Pizza
Business
Eli Lilly has made significant progress in addressing the shortage of their weight loss injection, Zepbound, and diabetes drug, Mounjaro. The U.S. Food and Drug Administration recently updated their drug shortage database to confirm that all doses of these medications are now available in the United States. This news comes after months of limited availability
Delta Air Lines CEO, Ed Bastian, recently extended a gesture of gratitude towards the employees of the airline who had to navigate through the chaos caused by a faulty CrowdStrike software update. This update resulted in significant disruptions that left thousands of customers and crew members stranded. The aftermath of this incident was alarming, with
Tadge Juechter, known as the “godfather” of the modern Corvette, has left an indelible mark on General Motors with his 47-year tenure at the Detroit automaker. His latest triumph comes in the form of the 2025 Chevrolet Corvette ZR1, which stands as the most powerful and fastest version of the iconic sports car to date.
The Summer Olympics in Paris have garnered attention from millions of viewers in the U.S., and a significant part of their experience has been the presence of Snoop Dogg. This iconic hip-hop artist has diversified his portfolio by becoming a sports commentator and entertainer at the Games in Paris. NBC Sports reported a 79% increase
In a groundbreaking move, Morgan Stanley is set to allow its financial advisors to offer bitcoin ETFs to select clients. This decision marks a significant shift in the stance of major Wall Street banks towards the cryptocurrency landscape. Morgan Stanley’s 15,000 financial advisors will now be able to recommend eligible clients to invest in the
Eli Lilly’s weight loss drug Zepbound has shown significant benefits in patients with a common type of heart failure and obesity, as per the late-stage trial data released by the company. The findings reveal that Zepbound, along with other popular GLP-1 drugs, offers health advantages beyond weight loss promotion and blood sugar regulation. The study